glp-1 otc drugs Why Is Everyone Excited About Medication? New GLP-1 drugs could suppress
Description
Yao R, Gala KS, Ghusn W, Abboud DM, Wallace FK, Vargas EJ
Specifically, the ELIXA (lixisenatide) trial studied patients with T2DM who had recent acute coronary syndrome and found that the addition of lixisenatide to conventional therapy did not result in a significant difference in cardiovascular endpoints relative to placebo (Table 1) [56]
2016 doi: 10.1016/S2213-8587(16)30267-4
Group, Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial, Lancet, 373 (2009) 473481
